Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double Blind, Controlled, Phase III Clinical Trial (Immunobridging Study) of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) in Healthy Population Aged 18 Years and Above

NCT05508477 is registered in ClinicalTrials.gov with Dr. Soetomo General Hospital as lead sponsor.

NCT NCT05508477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05508477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double Blind, Controlled, Phase III Clinical Trial (Immunobridging Study) of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) in Healthy Population Aged 18 Years and Above
Lead sponsor
Dr. Soetomo General Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
June 28, 2022
Completion date
May 28, 2023
Enrollment
4,005 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic, covid-19 vaccines